Drug intelligence / Profile preview

GNG-DE

Development stage: Phase 3
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Investigational product **GNG-DE** is a drug currently under clinical development and being evaluated in a clinical trial where it is administered as a 0.5 ml intramuscular injection in the deltoid muscle. The clinical trial design compares GNG-DE to Menactra, a licensed meningococcal conjugate vaccine, suggesting that GNG-DE may represent a vaccine candidate, potentially for meningococcal disease or a related indication. Mechanism of action, active ingredient, and detailed pharmacological information about GNG-DE are not specified in available sources.

Brand names: GNG-DE
Other names: GNG-DE

Beyond the preview

Go deeper on GNG-DE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNG-DE.

Explore the full profile